| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Neoplasms | 11 | 2023 | 1404 | 1.430 |
Why?
|
| Adenocarcinoma | 8 | 2020 | 1039 | 1.420 |
Why?
|
| Neoadjuvant Therapy | 6 | 2019 | 404 | 1.380 |
Why?
|
| Carcinoma, Hepatocellular | 10 | 2023 | 997 | 1.340 |
Why?
|
| Lymphatic Metastasis | 5 | 2019 | 450 | 1.150 |
Why?
|
| Peripheral Nervous System Diseases | 3 | 2021 | 137 | 0.930 |
Why?
|
| Stomach Neoplasms | 3 | 2021 | 565 | 0.900 |
Why?
|
| Lymph Nodes | 5 | 2019 | 397 | 0.820 |
Why?
|
| Health Services for Transgender Persons | 1 | 2021 | 1 | 0.730 |
Why?
|
| Gender Identity | 1 | 2021 | 73 | 0.690 |
Why?
|
| Veterans | 7 | 2024 | 1790 | 0.680 |
Why?
|
| Patient Transfer | 1 | 2021 | 110 | 0.680 |
Why?
|
| Natural Language Processing | 2 | 2024 | 71 | 0.670 |
Why?
|
| Transgender Persons | 1 | 2021 | 68 | 0.660 |
Why?
|
| Cancer Survivors | 2 | 2021 | 252 | 0.660 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2019 | 398 | 0.640 |
Why?
|
| Fatigue | 1 | 2021 | 198 | 0.640 |
Why?
|
| Physician-Patient Relations | 2 | 2021 | 447 | 0.610 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 237 | 0.600 |
Why?
|
| Exercise Therapy | 1 | 2021 | 185 | 0.600 |
Why?
|
| Gastrectomy | 2 | 2021 | 102 | 0.600 |
Why?
|
| Neoplasm Staging | 8 | 2020 | 1375 | 0.560 |
Why?
|
| Attitude of Health Personnel | 2 | 2021 | 724 | 0.540 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 1854 | 0.520 |
Why?
|
| Rectal Neoplasms | 1 | 2018 | 81 | 0.520 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 66 | 0.480 |
Why?
|
| Wearable Electronic Devices | 3 | 2024 | 108 | 0.470 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 101 | 0.460 |
Why?
|
| Electronic Health Records | 3 | 2024 | 804 | 0.410 |
Why?
|
| Aged | 26 | 2024 | 21584 | 0.410 |
Why?
|
| Databases, Factual | 3 | 2018 | 1256 | 0.390 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 1599 | 0.380 |
Why?
|
| Hospitals | 3 | 2020 | 442 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 1352 | 0.350 |
Why?
|
| HIV Infections | 1 | 2023 | 2023 | 0.340 |
Why?
|
| Middle Aged | 21 | 2024 | 29081 | 0.330 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 7197 | 0.330 |
Why?
|
| Retrospective Studies | 16 | 2023 | 17580 | 0.320 |
Why?
|
| Interprofessional Relations | 1 | 2011 | 158 | 0.310 |
Why?
|
| Physician's Role | 1 | 2011 | 171 | 0.310 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 1467 | 0.310 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2020 | 87 | 0.300 |
Why?
|
| Algorithms | 1 | 2016 | 1730 | 0.290 |
Why?
|
| Communication | 2 | 2022 | 541 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 1136 | 0.280 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 169 | 0.280 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 1305 | 0.270 |
Why?
|
| Esophagectomy | 2 | 2018 | 67 | 0.270 |
Why?
|
| Male | 26 | 2024 | 65658 | 0.270 |
Why?
|
| Humans | 36 | 2024 | 133529 | 0.260 |
Why?
|
| Chemoradiotherapy | 2 | 2018 | 127 | 0.260 |
Why?
|
| Female | 24 | 2024 | 71561 | 0.240 |
Why?
|
| Colorectal Neoplasms | 1 | 2011 | 647 | 0.220 |
Why?
|
| Primary Health Care | 1 | 2011 | 804 | 0.220 |
Why?
|
| United States | 12 | 2021 | 11761 | 0.220 |
Why?
|
| Neoplasms | 4 | 2024 | 2987 | 0.210 |
Why?
|
| Esophageal Neoplasms | 2 | 2018 | 392 | 0.210 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 78 | 0.190 |
Why?
|
| Liver Cirrhosis | 3 | 2020 | 899 | 0.190 |
Why?
|
| Colonic Neoplasms | 2 | 2017 | 269 | 0.190 |
Why?
|
| Adult | 11 | 2021 | 31787 | 0.180 |
Why?
|
| Frailty | 1 | 2024 | 135 | 0.180 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2016 | 426 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 786 | 0.180 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2018 | 34 | 0.170 |
Why?
|
| Treatment Outcome | 9 | 2019 | 13101 | 0.170 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 965 | 0.170 |
Why?
|
| Emotions | 2 | 2021 | 367 | 0.160 |
Why?
|
| Palliative Care | 2 | 2018 | 462 | 0.160 |
Why?
|
| False Negative Reactions | 1 | 2019 | 89 | 0.150 |
Why?
|
| Young Adult | 5 | 2021 | 9980 | 0.150 |
Why?
|
| Comorbidity | 3 | 2019 | 1626 | 0.140 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 307 | 0.140 |
Why?
|
| Hospice Care | 1 | 2018 | 31 | 0.140 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 1159 | 0.140 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2017 | 23 | 0.140 |
Why?
|
| Gallbladder Neoplasms | 1 | 2017 | 15 | 0.140 |
Why?
|
| Rectum | 1 | 2018 | 114 | 0.130 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 105 | 0.130 |
Why?
|
| Myasthenia Gravis | 1 | 2017 | 71 | 0.130 |
Why?
|
| Stomach | 1 | 2019 | 272 | 0.130 |
Why?
|
| Preoperative Care | 1 | 2019 | 373 | 0.130 |
Why?
|
| Pancreatectomy | 1 | 2017 | 149 | 0.130 |
Why?
|
| Veterans Health | 1 | 2018 | 180 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 136 | 0.120 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 121 | 0.120 |
Why?
|
| Cholangiocarcinoma | 1 | 2017 | 121 | 0.120 |
Why?
|
| Cohort Studies | 7 | 2021 | 5205 | 0.120 |
Why?
|
| Telemedicine | 1 | 2022 | 507 | 0.120 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 911 | 0.120 |
Why?
|
| Motor Activity | 1 | 2019 | 528 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 128 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2019 | 1268 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 230 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 317 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 334 | 0.110 |
Why?
|
| Adolescent | 5 | 2021 | 20606 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 774 | 0.110 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2016 | 715 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 286 | 0.110 |
Why?
|
| Registries | 2 | 2019 | 1591 | 0.110 |
Why?
|
| Survival Analysis | 4 | 2017 | 1584 | 0.100 |
Why?
|
| Embolization, Therapeutic | 1 | 2015 | 225 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 2311 | 0.100 |
Why?
|
| Hospitalization | 1 | 2021 | 1912 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2017 | 541 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2017 | 752 | 0.090 |
Why?
|
| Referral and Consultation | 2 | 2013 | 573 | 0.090 |
Why?
|
| Quinazolines | 1 | 2012 | 185 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 1312 | 0.090 |
Why?
|
| Outpatients | 1 | 2013 | 277 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 740 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 1053 | 0.090 |
Why?
|
| Quality of Life | 1 | 2021 | 2160 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 2153 | 0.080 |
Why?
|
| Patient Care Management | 1 | 2011 | 68 | 0.080 |
Why?
|
| Piperidines | 1 | 2012 | 240 | 0.080 |
Why?
|
| Physicians, Primary Care | 1 | 2011 | 99 | 0.080 |
Why?
|
| Survival Rate | 3 | 2021 | 2203 | 0.080 |
Why?
|
| Perception | 1 | 2011 | 238 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2011 | 246 | 0.080 |
Why?
|
| Gait | 2 | 2021 | 141 | 0.080 |
Why?
|
| Hospitals, Veterans | 1 | 2011 | 365 | 0.080 |
Why?
|
| Inpatients | 1 | 2013 | 552 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 1558 | 0.070 |
Why?
|
| Prognosis | 1 | 2018 | 5052 | 0.070 |
Why?
|
| Terminally Ill | 1 | 2008 | 29 | 0.070 |
Why?
|
| Attitude to Death | 1 | 2008 | 39 | 0.070 |
Why?
|
| Qualitative Research | 1 | 2011 | 659 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2011 | 578 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2008 | 262 | 0.060 |
Why?
|
| Fear | 2 | 2021 | 205 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1912 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 3990 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 1697 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2012 | 4918 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2008 | 605 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1468 | 0.050 |
Why?
|
| Accidental Falls | 1 | 2021 | 119 | 0.040 |
Why?
|
| Obesity | 1 | 2011 | 2438 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 2753 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2018 | 3725 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 1463 | 0.030 |
Why?
|
| Attention | 1 | 2019 | 203 | 0.030 |
Why?
|
| Exercise | 1 | 2024 | 873 | 0.030 |
Why?
|
| Age Factors | 2 | 2016 | 2956 | 0.030 |
Why?
|
| Postural Balance | 1 | 2019 | 133 | 0.030 |
Why?
|
| Diplopia | 1 | 2017 | 38 | 0.030 |
Why?
|
| Memory Disorders | 1 | 2019 | 235 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 280 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 134 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 176 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 378 | 0.030 |
Why?
|
| Dyspnea | 1 | 2017 | 159 | 0.030 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2015 | 28 | 0.030 |
Why?
|
| Health Services | 1 | 2016 | 73 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 2016 | 134 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 990 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 675 | 0.030 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2016 | 59 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1195 | 0.030 |
Why?
|
| Biomarkers | 1 | 2024 | 3417 | 0.030 |
Why?
|
| Risk Factors | 2 | 2018 | 10970 | 0.020 |
Why?
|
| Independent Living | 1 | 2013 | 72 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 155 | 0.020 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 365 | 0.020 |
Why?
|
| Patient Admission | 1 | 2013 | 190 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2017 | 701 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 3450 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2012 | 302 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 448 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 3097 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 725 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 446 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 336 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2013 | 388 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 6545 | 0.020 |
Why?
|
| Existentialism | 1 | 2008 | 3 | 0.020 |
Why?
|
| Nursing Methodology Research | 1 | 2008 | 14 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1870 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 1068 | 0.020 |
Why?
|
| Grief | 1 | 2008 | 20 | 0.020 |
Why?
|
| New York | 1 | 2008 | 73 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 829 | 0.020 |
Why?
|
| Spirituality | 1 | 2008 | 52 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 612 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 2678 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 1251 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 2249 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 177 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 631 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2008 | 233 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5453 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 1759 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2008 | 431 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 1166 | 0.010 |
Why?
|
| Family | 1 | 2008 | 595 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 934 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 2124 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2011 | 6586 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 36121 | 0.010 |
Why?
|